Samsung Bioepis and C-Bridge Capital to Commercialize Biosimilars in China

Samsung Bioepis announced in a February 11, 2019 press release that it will expand in mainland China through a licensing agreement with C-Bridge Capital. The agreement covers multiple biosimilar candidates from Samsung Bioepis, including third-wave biosimilar candidates SB11 and SB12, which reference Lucentis (ranibizumab) and Soliris (eculizumab), respectively, as well as SB3, a biosimilar candidate referencing Herceptin (trastuzumab).

Under the agreement, C-Bridge will establish a new biopharmaceutical company, AffaMed Therapeutics, which will collaborate with Samsung Bioepis across a number of areas, including clinical development, regulatory registration, and commercialization in China. Samsung Bioepis will receive an upfront payment, as well as royalties on sales. Additional financial details were not disclosed.

“We want to play an important role in widening access to high-quality healthcare for patients throughout China. C-Bridge is the right partner for this mission as evidenced in its exceptional track record of successfully turning portfolio companies like AffaMed Therapeutics into leading biopharmaceutical companies in China and beyond,” said Christopher Hansung Ko, president and CEO, Samsung Bioepis, in the press release. 

Source: Samsung Bioepis